Thursday 16 October, 2025
Objectives: JDQ443 is an irreversible, covalent KRASG12C inhibitor that is currently being evaluated in clinical trials in patients with non-small…
Read morePoster: Drug/Disease Modelling - Oncology
Population pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration
Thursday 16 October, 2025
Introduction: Lutathera® (177Lu-Dotatate) is a peptide receptor radionuclide therapy indicated in treating gastroenteropancreatic neuroendocrine tumors overexpressing somatostatin receptors. It is…
Read moreA population approach to compare the impact of two amino acid solutions on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors
Thursday 16 October, 2025
Introduction: Lutathera® (177Lu-Dotatate) is a peptide receptor radionuclide therapy indicated in the treatment of gastroenteropancreatic neuroendocrine tumors overexpressing somatostatin receptors. It…
Read moreA translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues
Thursday 16 October, 2025
Objectives: MEN1703 is a novel dual kinase inhibitor targeting PIM and FLT3 kinases, currently under investigation in patients with acute…
Read morePopulation Pharmacokinetics of cabozantinib in adult metastatic renal cell carcinoma patients: evaluation of real-world data
Thursday 16 October, 2025
Introduction: Cabozantinib, a second-generation receptor tyrosine kinase inhibitor, is approved for the treatment of metastatic renal cell carcinoma (mRCC) at a…
Read morePopulation pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma
Thursday 16 October, 2025
Introduction: Pazopanib is a multi-target receptor tyrosine kinase inhibitor (TKI), and part of the current standard of care of metastatic…
Read moreModel-informed pazopanib dose optimization in real-world cancer patients
Thursday 16 October, 2025
Introduction: Pazopanib is currently used for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) at an…
Read morePopulation pharmacokinetics of selpercatinib in patients with an advanced solid tumor, including RET fusion-positive NSCLC, RET-mutant MTC, and other tumors with increased RET activity
Thursday 16 October, 2025
Objectives: Selpercatinib, a first-in-class highly selective and potent rearranged during transfection (RET) kinase inhibitor with central nervous system activity, is…
Read moreThe comparison of pharmacoeconomic and pharmacometric modelling to improve cost-effectiveness assessment of sunitinib in GIST.
Thursday 16 October, 2025
Objectives: Governmental organisations are continuously making difficult decisions regarding regulatory approval, balancing drug efficacy against toxicity and costs. Pharmacoeconomic (PE)…
Read moreOptimizing the Dose Escalation of a new anti-CD73 monoclonal antibody for target Inhibition: A Comprehensive Preclinical and Clinical Modelling Approach
Thursday 16 October, 2025
Objectives: S095024 (Sym024) is a monoclonal Fc-effector function attenuated antibody inhibiting CD73. CD73 is a key enzyme involved in the…
Read more